NCIRS webinar recording now available: Living with COVID-19: Getting back to immunisation business as usual
A recording of the NCIRS webinar Living with COVID-19: Getting back to immunisation business as usual is now available. The session featured a panel of expert speakers including MVEC’s A/Prof Nigel Crawford and covered:
- an update on Australian COVID‑19 vaccine recommendations
- vaccine and infection immunity duration – where are we headed?
- new COVID-19 vaccines – do we need to change our strategy in response to new variants?
- COVID-19, routine immunisation and emerging from the pandemic
रिकॉर्डिंग तक पहुँचने के लिए, कृपया नीचे दिए गए लिंक पर क्लिक करें:
NCIRS webinar: Living with COVID-19: Getting back to immunisation business as usual
COVID-19 वैक्सीन प्रशासन त्रुटियों पर ATAGI नैदानिक मार्गदर्शन
ATAGI has provided the below guidance for clinicians outlining the appropriate management of common COVID-19 vaccine administration errors. It includes scenarios where the vaccine is administered in the following circumstances:
- Via the incorrect site/route
- At a higher/lower dose
- Following incorrect storage and handling
- In an unapproved age group
- Mixed vaccine schedules
- With incorrect intervals
It is important to note that in Victoria, any vaccine administration error should be reported to सैफविक. Following the identification of a vaccine error, open disclosure with the vaccine recipient is important and addressing the cause of the error will prevent errors from occurring again in the future.
To read the full guideline, follow the link below:
COVID-19 वैक्सीन प्रशासन त्रुटियों पर ATAGI नैदानिक मार्गदर्शन
New resource: NCIRS Decision aid (5–15 years): Should I get the COVID-19 vaccine for my child?
NCIRS have designed a new decision aid resource to help families make an informed decision about whether COVID-19 vaccination is right for their children.
The tool provides evidence-based information about the disease and the vaccine and takes the user through five simple steps to help weigh up the risks and benefits of vaccination.
To access the decision guide, please click on the link below.
New resource: NCIRS Decision aid (5–15 years): Should I get the COVID-19 vaccine for my child?
Clinical recommendations for COVID-19 vaccines- updated booster advice
The Australian Technical Advisory Group on Immunisation (ATAGI) have provided updated recommendations on the use of booster doses of COVID-19 vaccines:
- Individuals aged 18 years and above are recommended to receive a single booster dose of either mRNA vaccine (Pfizer या Moderna), 3 months after the completion of a primary course of vaccination.
- Individuals aged 16-17 years are recommended to receive a single dose of Comirnaty (Pfizer) as their booster, 3 months following the completion of their primary course. Alternate COVID-19 vaccine brands are not registered for use as a booster dose in this age group.
- Whilst नुवाक्सोविड (नोवावैक्स) is not TGA-registered for use as a booster dose, ATAGI recommends that it may be used as a booster in individuals aged 18 years or older in circumstances where there is a contraindication to mRNA vaccines. There is limited safety and efficacy data to support the use of Nuvaxovid as a booster dose, however there are no theoretical concerns.
- वैक्सजेव्रिया (एस्ट्राजेनेका) is no longer recommended for use as a booster dose. Individuals who have already received Vaxzevria (AstraZeneca) as their booster dose do not need a repeat booster dose of an alternate brand.
For further information regarding the ATAGI recommendations on the use of a booster dose of COVID-19 vaccine, please refer to the links below:
ATAGI recommendations on the use of a booster dose of COVID-19 vaccine
ATAGI recommendations on the use of Spikevax (Moderna) COVID-19 vaccine in children aged 6 to 11 years
Following the TGA’s provisional approval, ATAGI has put forth a guideline that recommends the use of Moderna’s COVID-19 vaccine (Spikevax) in children aged 6 to 11 years.
Clinical data supports that Spikevax produces a strong immune response and reduces the likelihood of children in this cohort developing COVID-19.
This statement addresses the recommendations, considerations and rationale for the use of Moderna’s COVID-19 vaccine in children aged 6 to 11.
पूरा बयान पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें।
बातचीत: मॉडर्ना का टीका अब 6 से 11 साल के बच्चों के लिए उपलब्ध है। यहां माता-पिता को जानने की जरूरत है
मॉडर्न COVID-19 वैक्सीन को अब 6 से 11 साल की उम्र के बच्चों में इस्तेमाल के लिए मंजूरी मिल गई है। ऑस्ट्रेलिया के प्राइमरी-स्कूल जाने वाले आधे से भी कम बच्चों को कोविड वैक्सीन की पहली खुराक मिली है, मॉडर्न के कोविड वैक्सीन की मंज़ूरी माता-पिता को अपने बच्चों को गंभीर बीमारी से बचाने का एक अतिरिक्त अवसर प्रदान करती है।
किडकोव क्लिनिकल परीक्षण के बाद, यह लेख 6 से 11 साल के समूह में मॉडर्न के COVID-19 वैक्सीन के उपयोग के लिए चल रही सुरक्षा और प्रभावकारिता के साथ-साथ विचारों और प्रशासनिक सिफारिशों की पड़ताल करता है।
पूरा लेख पढ़ने के लिए, नीचे दिए गए लिंक का अनुसरण करें।
ATAGI update following weekly COVID-19 meeting – 16 February 2022
ATAGI held their weekly meeting on Wednesday 16 February to discuss the latest developments and recommendations relating to COVID-19 immunisations.
The meeting addressed the use of Moderna’s COVID-19 vaccine in children aged 6 to 11 years, as well as, the use of Novavax’s COVID-19 vaccine as a booster and recommendations regarding the vaccine dose interval for children.
To read the full update, follow the link below:
ATAGI update following weekly COVID-19 meeting – 16 February 2022
NCIRS Webinar - Living with COVID-19: Getting back to immunisation business as usual
NCIRS will be hosting a webinar on Thursday 3 March featuring a panel of expert speakers including MVEC’s A/Prof Nigel Crawford. The topic for the webinar is Living with COVID-19: Getting back to immunisation business as usual and will cover:
- an update on Australian COVID‑19 vaccine recommendations
- COVID-19 and routine immunisation programs regionally and globally – what’s needed
- new COVID-19 vaccines – do we need to change our strategy in response to new variants?
Further information and details on registration can be found via the link below:
NCIRS Webinar - Living with COVID-19: Getting back to immunisation business as usual
ABC News: Chickenpox defies COVID-19 restrictions, prompting vaccination warning
Throughout the pandemic, the highly transmissible varicella zoster virus, which causes chickenpox has continued to spread with more than 10,000 cases recorded in Queensland last year and similar levels observed in 2020.
While the pandemic has shown social and physical distancing to be very effective in limiting the spread of diseases, this article reveals that we can expect to see a number of infectious diseases increase as measures are relaxed.
Immunising against the varicella zoster virus is the best way to protect against infection. Data shows that the vaccine is 95 to 99 per cent effective at preventing severe chickenpox so there is a need to encourage individuals – especially pregnant women – to ensure they are up to date with their vaccinations.
लेख को पूरा पढ़ने के लिए कृपया नीचे दिए गए लिंक पर क्लिक करें।
ABC News: Chickenpox defies COVID-19 restrictions, prompting vaccination warning
The Conversation: Do COVID boosters cause more or fewer side effects? How quickly does protection wane? Your questions answered
With more than 2,400 people currently in hospital, the Australian Technical Advisory Group on Immunisation (ATAGI) recommends Australians aged 16 years and older have a COVID-19 booster vaccine to ensure high levels of protection against severe disease and hospitalisation. A booster dose of the COVID vaccine, three months following the completion of the primary course can provide a similar level of protection against Omicron as two primary doses against Delta.
Additionally, data shows that the booster dose renders milder side effects compared to the first 2 doses with less than 1% of people reporting the need for a medical consultation.
This article explores the benefits of a booster vaccine compared to the primary 2 doses, the time frame recommendation for receiving a booster following COVID infection, and whether additional vaccine doses will be required in the future.
पूरा लेख पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें: